Menogaril in the treatment of relapsed multiple myeloma. A phase II trial of the Cancer Center of Wake Forest University
Fifteen patients with relapsed multiple myeloma (MM) were treated with menogaril 160 mg/m2 intravenously (IV) every 28 days. No responses were seen: 8 patients had stable disease, 4 progressed after one course of therapy, and 3 patients were removed from study after 1 course for other reasons. Four...
Gespeichert in:
| Veröffentlicht in: | Investigational new drugs 1992-04, Vol.10 (1), p.35-37 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 37 |
|---|---|
| container_issue | 1 |
| container_start_page | 35 |
| container_title | Investigational new drugs |
| container_volume | 10 |
| creator | Cruz, J M Case, L D Dalton, H B Ramseur, W L Richards, 2nd, F Jackson, D V Muss, H B Zekan, P J Brodkin, R A Brown, R C |
| description | Fifteen patients with relapsed multiple myeloma (MM) were treated with menogaril 160 mg/m2 intravenously (IV) every 28 days. No responses were seen: 8 patients had stable disease, 4 progressed after one course of therapy, and 3 patients were removed from study after 1 course for other reasons. Four of the 8 patients with stable disease had an improved performance status, and 3 had a decrease in analgesic use. The major toxicity was myelosuppression. The median progression-free interval was 3.0 months with a range of 0.7 to 22 months and median survival was 11.3 months with a range of 0.7 to 39+ months. Menogaril displays little activity in patients with previously treated MM. |
| doi_str_mv | 10.1007/BF01275478 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF01275478</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1535064</sourcerecordid><originalsourceid>FETCH-LOGICAL-c241t-2d7ba6c3f18f72659d5239c92522228c017c1d26956c3c6fb483ca3407a4e1c13</originalsourceid><addsrcrecordid>eNpFkEtLAzEUhYMotVY37oWshal5TJKZZR0cLVTcWFwOaeaOjc6LJBX7702p0Ls5cPnOWXwI3VIyp4Soh8eSUKZEqrIzNKVC8YTIVJ6jKaFSJTLP1SW68v6LEMJzlU7QhAouIjNFv6_QD5_a2RbbHoct4OBAhw76gIcGO2j16KHG3a4NdmwBd3toh07P8QKPW-0BL5exYnV7wA_9QvcGHC7iQoz4_NDfgMvBgQ943dsfcN6G_TW6aHTr4eY_Z2hdPr0XL8nq7XlZLFaJYSkNCavVRkvDG5o1ikmR14Lx3ORMsHiZIVQZWjOZiwgZ2WzSjBvNU6J0CtRQPkP3x13jBu8dNNXobKfdvqKkOtirTvYifHeEx92mg_qEHnXxPyrZaWo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Menogaril in the treatment of relapsed multiple myeloma. A phase II trial of the Cancer Center of Wake Forest University</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Cruz, J M ; Case, L D ; Dalton, H B ; Ramseur, W L ; Richards, 2nd, F ; Jackson, D V ; Muss, H B ; Zekan, P J ; Brodkin, R A ; Brown, R C</creator><creatorcontrib>Cruz, J M ; Case, L D ; Dalton, H B ; Ramseur, W L ; Richards, 2nd, F ; Jackson, D V ; Muss, H B ; Zekan, P J ; Brodkin, R A ; Brown, R C</creatorcontrib><description>Fifteen patients with relapsed multiple myeloma (MM) were treated with menogaril 160 mg/m2 intravenously (IV) every 28 days. No responses were seen: 8 patients had stable disease, 4 progressed after one course of therapy, and 3 patients were removed from study after 1 course for other reasons. Four of the 8 patients with stable disease had an improved performance status, and 3 had a decrease in analgesic use. The major toxicity was myelosuppression. The median progression-free interval was 3.0 months with a range of 0.7 to 22 months and median survival was 11.3 months with a range of 0.7 to 39+ months. Menogaril displays little activity in patients with previously treated MM.</description><identifier>ISSN: 0167-6997</identifier><identifier>EISSN: 1573-0646</identifier><identifier>DOI: 10.1007/BF01275478</identifier><identifier>PMID: 1535064</identifier><language>eng</language><publisher>United States</publisher><subject>Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Drug Administration Schedule ; Drug Evaluation ; Humans ; Menogaril ; Multiple Myeloma - drug therapy ; Nogalamycin - administration & dosage ; Nogalamycin - adverse effects ; Nogalamycin - analogs & derivatives</subject><ispartof>Investigational new drugs, 1992-04, Vol.10 (1), p.35-37</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c241t-2d7ba6c3f18f72659d5239c92522228c017c1d26956c3c6fb483ca3407a4e1c13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1535064$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cruz, J M</creatorcontrib><creatorcontrib>Case, L D</creatorcontrib><creatorcontrib>Dalton, H B</creatorcontrib><creatorcontrib>Ramseur, W L</creatorcontrib><creatorcontrib>Richards, 2nd, F</creatorcontrib><creatorcontrib>Jackson, D V</creatorcontrib><creatorcontrib>Muss, H B</creatorcontrib><creatorcontrib>Zekan, P J</creatorcontrib><creatorcontrib>Brodkin, R A</creatorcontrib><creatorcontrib>Brown, R C</creatorcontrib><title>Menogaril in the treatment of relapsed multiple myeloma. A phase II trial of the Cancer Center of Wake Forest University</title><title>Investigational new drugs</title><addtitle>Invest New Drugs</addtitle><description>Fifteen patients with relapsed multiple myeloma (MM) were treated with menogaril 160 mg/m2 intravenously (IV) every 28 days. No responses were seen: 8 patients had stable disease, 4 progressed after one course of therapy, and 3 patients were removed from study after 1 course for other reasons. Four of the 8 patients with stable disease had an improved performance status, and 3 had a decrease in analgesic use. The major toxicity was myelosuppression. The median progression-free interval was 3.0 months with a range of 0.7 to 22 months and median survival was 11.3 months with a range of 0.7 to 39+ months. Menogaril displays little activity in patients with previously treated MM.</description><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Drug Administration Schedule</subject><subject>Drug Evaluation</subject><subject>Humans</subject><subject>Menogaril</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Nogalamycin - administration & dosage</subject><subject>Nogalamycin - adverse effects</subject><subject>Nogalamycin - analogs & derivatives</subject><issn>0167-6997</issn><issn>1573-0646</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtLAzEUhYMotVY37oWshal5TJKZZR0cLVTcWFwOaeaOjc6LJBX7702p0Ls5cPnOWXwI3VIyp4Soh8eSUKZEqrIzNKVC8YTIVJ6jKaFSJTLP1SW68v6LEMJzlU7QhAouIjNFv6_QD5_a2RbbHoct4OBAhw76gIcGO2j16KHG3a4NdmwBd3toh07P8QKPW-0BL5exYnV7wA_9QvcGHC7iQoz4_NDfgMvBgQ943dsfcN6G_TW6aHTr4eY_Z2hdPr0XL8nq7XlZLFaJYSkNCavVRkvDG5o1ikmR14Lx3ORMsHiZIVQZWjOZiwgZ2WzSjBvNU6J0CtRQPkP3x13jBu8dNNXobKfdvqKkOtirTvYifHeEx92mg_qEHnXxPyrZaWo</recordid><startdate>19920401</startdate><enddate>19920401</enddate><creator>Cruz, J M</creator><creator>Case, L D</creator><creator>Dalton, H B</creator><creator>Ramseur, W L</creator><creator>Richards, 2nd, F</creator><creator>Jackson, D V</creator><creator>Muss, H B</creator><creator>Zekan, P J</creator><creator>Brodkin, R A</creator><creator>Brown, R C</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19920401</creationdate><title>Menogaril in the treatment of relapsed multiple myeloma. A phase II trial of the Cancer Center of Wake Forest University</title><author>Cruz, J M ; Case, L D ; Dalton, H B ; Ramseur, W L ; Richards, 2nd, F ; Jackson, D V ; Muss, H B ; Zekan, P J ; Brodkin, R A ; Brown, R C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c241t-2d7ba6c3f18f72659d5239c92522228c017c1d26956c3c6fb483ca3407a4e1c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Drug Administration Schedule</topic><topic>Drug Evaluation</topic><topic>Humans</topic><topic>Menogaril</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Nogalamycin - administration & dosage</topic><topic>Nogalamycin - adverse effects</topic><topic>Nogalamycin - analogs & derivatives</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cruz, J M</creatorcontrib><creatorcontrib>Case, L D</creatorcontrib><creatorcontrib>Dalton, H B</creatorcontrib><creatorcontrib>Ramseur, W L</creatorcontrib><creatorcontrib>Richards, 2nd, F</creatorcontrib><creatorcontrib>Jackson, D V</creatorcontrib><creatorcontrib>Muss, H B</creatorcontrib><creatorcontrib>Zekan, P J</creatorcontrib><creatorcontrib>Brodkin, R A</creatorcontrib><creatorcontrib>Brown, R C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Investigational new drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cruz, J M</au><au>Case, L D</au><au>Dalton, H B</au><au>Ramseur, W L</au><au>Richards, 2nd, F</au><au>Jackson, D V</au><au>Muss, H B</au><au>Zekan, P J</au><au>Brodkin, R A</au><au>Brown, R C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Menogaril in the treatment of relapsed multiple myeloma. A phase II trial of the Cancer Center of Wake Forest University</atitle><jtitle>Investigational new drugs</jtitle><addtitle>Invest New Drugs</addtitle><date>1992-04-01</date><risdate>1992</risdate><volume>10</volume><issue>1</issue><spage>35</spage><epage>37</epage><pages>35-37</pages><issn>0167-6997</issn><eissn>1573-0646</eissn><abstract>Fifteen patients with relapsed multiple myeloma (MM) were treated with menogaril 160 mg/m2 intravenously (IV) every 28 days. No responses were seen: 8 patients had stable disease, 4 progressed after one course of therapy, and 3 patients were removed from study after 1 course for other reasons. Four of the 8 patients with stable disease had an improved performance status, and 3 had a decrease in analgesic use. The major toxicity was myelosuppression. The median progression-free interval was 3.0 months with a range of 0.7 to 22 months and median survival was 11.3 months with a range of 0.7 to 39+ months. Menogaril displays little activity in patients with previously treated MM.</abstract><cop>United States</cop><pmid>1535064</pmid><doi>10.1007/BF01275478</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6997 |
| ispartof | Investigational new drugs, 1992-04, Vol.10 (1), p.35-37 |
| issn | 0167-6997 1573-0646 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_BF01275478 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Drug Administration Schedule Drug Evaluation Humans Menogaril Multiple Myeloma - drug therapy Nogalamycin - administration & dosage Nogalamycin - adverse effects Nogalamycin - analogs & derivatives |
| title | Menogaril in the treatment of relapsed multiple myeloma. A phase II trial of the Cancer Center of Wake Forest University |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A59%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Menogaril%20in%20the%20treatment%20of%20relapsed%20multiple%20myeloma.%20A%20phase%20II%20trial%20of%20the%20Cancer%20Center%20of%20Wake%20Forest%20University&rft.jtitle=Investigational%20new%20drugs&rft.au=Cruz,%20J%20M&rft.date=1992-04-01&rft.volume=10&rft.issue=1&rft.spage=35&rft.epage=37&rft.pages=35-37&rft.issn=0167-6997&rft.eissn=1573-0646&rft_id=info:doi/10.1007/BF01275478&rft_dat=%3Cpubmed_cross%3E1535064%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/1535064&rfr_iscdi=true |